Equities Analysts Offer Predictions for ABEO FY2026 Earnings

Abeona Therapeutics Inc. (NASDAQ:ABEO – Free Report) – Equities researchers at HC Wainwright boosted their FY2026 EPS estimates for shares of Abeona Therapeutics in a research report issued to clients and investors on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($0.96) per share for the year, up from their prior estimate of ($1.15). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2026 earnings at ($0.22) EPS, Q1 2027 earnings at ($0.24) EPS, Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.20) EPS, Q4 2027 earnings at ($0.17) EPS and FY2027 earnings at ($0.82) EPS.

Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last issued its earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.09. Abeona Therapeutics had a negative net margin of 160.30% and a negative return on equity of 44.82%. The business had revenue of $13.49 million for the quarter, compared to the consensus estimate of $14.82 million.

Other equities research analysts have also issued research reports about the company. Oppenheimer reaffirmed an “outperform” rating and issued a $21.00 price objective (down from $22.00) on shares of Abeona Therapeutics in a report on Friday, August 14th. Cantor Fitzgerald boosted their target price on Abeona Therapeutics from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, September 18th. Roth Capital assumed coverage on Abeona Therapeutics in a research note on Thursday, September 17th. They set a “buy” rating and a $17.00 target price for the company. UBS Group reissued a “buy” rating on shares of Abeona Therapeutics in a report on Friday, September 25th. Finally, Weiss Ratings cut Abeona Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, November 10th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $21.00.

View Our Latest Stock Report on ABEO

Abeona Therapeutics Stock Up 7.4%

NASDAQ ABEO opened at $2.60 on Monday. The stock has a market capitalization of $148.59 million, a P/E ratio of -2.43 and a beta of 1.50. Abeona Therapeutics has a 52-week low of $2.09 and a 52-week high of $7.65. The firm has a 50-day moving average price of $4.63 and a 200 day moving average price of $5.38.

Insider Buying and Selling at Abeona Therapeutics

In other news, CFO Joseph Vazzano sold 9,191 shares of the stock in a transaction dated Tuesday, September 29th. The shares were sold at an average price of $5.16, for a total value of $47,425.56. Following the completion of the transaction, the chief financial officer owned 482,888 shares in the company, valued at $2,491,702.08. This trade represents a 1.87% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Faith Charles purchased 15,000 shares of the business’s stock in a transaction dated Friday, November 13th. The stock was bought at an average price of $2.29 per share, with a total value of $34,350.00. Following the acquisition, the director directly owned 191,407 shares in the company, valued at approximately $438,322.03. This represents a 8.50% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders sold 55,428 shares of company stock worth $296,508. Company insiders own 7.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ABEO. AIGH Capital Management LLC acquired a new stake in shares of Abeona Therapeutics during the 3rd quarter valued at approximately $15,225,000. AWM Investment Company Inc. purchased a new stake in shares of Abeona Therapeutics during the 2nd quarter worth approximately $9,184,000. Nan Fung Trinity HK Ltd. grew its holdings in shares of Abeona Therapeutics by 336.6% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 552,270 shares of the biopharmaceutical company’s stock worth $2,899,000 after acquiring an additional 425,770 shares during the period. Simplify Asset Management Inc. acquired a new stake in shares of Abeona Therapeutics in the 3rd quarter worth approximately $1,451,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Abeona Therapeutics in the 2nd quarter worth approximately $1,262,000. 80.56% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Abeona Therapeutics

Investors following ABEO have been watching these headlines:

  • Positive Sentiment: Director Faith Charles bought 15,000 shares for about $34,350, increasing her stake by 8.5% to 191,407 shares. The insider purchase may be viewed as a confidence signal. SEC filing
  • Neutral Sentiment: HC Wainwright maintained its Buy rating. It raised its FY2026 EPS estimate to a loss of $0.96 from $1.15, while forecasting a $0.82 loss per share for FY2027. Abeona Therapeutics analyst coverage
  • Negative Sentiment: The analyst lowered estimates across Q1–Q4 2027, including cutting FY2027 EPS to a loss of $0.82 from $0.49. These revisions suggest a weaker earnings outlook and could weigh on shares, partially offsetting the insider buying.

About Abeona Therapeutics

(Get Free Report)

Abeona Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for serious and rare diseases. Its work includes treatments designed to address the underlying genetic causes of disease. The company’s lead product, ZEVASKYN (prademagene zamikeracel), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder. Made from a patient’s skin cells, the therapy uses genetic modification to help cells produce type VII collagen and is applied to wounds.

Featured Articles

Earnings History and Estimates for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.